期刊文献+

FEZ1和p16在宫颈上皮内瘤变中的表达及临床意义 被引量:1

Expression and clinical significance of FEZ1 and p16 in cervical intraepithelial neoplasia
原文传递
导出
摘要 目的 探讨FEZ1和p16在宫颈上皮内瘤变(CIN)中的表达及其相关性.方法 应用免疫组织化学方法检测93例CIN组织及10例正常宫颈组织中FEZ1、p16的表达情况.结果 在正常宫颈组织、CIN Ⅰ、CINⅡ、CINⅢ中,FEZ1的阳性表达率分别为90.0%(9/10)、67.9%(19/28)、36.0% (9/25)、22.5%(9/40),p16的阳性表达率分别为10.0% (1/10)、32.1%(9/28)、76.0%(19/25)、92.5%(37/40).FEZ1在CIN中的阳性表达率明显低于正常宫颈组织,p16则高于正常宫颈组织,差异均有统计学意义(P<0.05).二者在CIN Ⅰ与CINⅢ间阳性表达率比较差异均有统计学意义(P<0.01),在CINⅡ与CINⅢ间阳性表达率比较差异无统计学意义(P>0.05).FEZ1与p16在CIN中的表达呈负相关(r=-0.712,P<0.01).结论 FEZ1的异常低表达与p16的异常高表达参与了CIN的发生、发展过程,二者的联合检测可为CIN的诊断提供新的依据. Objective To investigate the expressions and the relationship of FEZ1 and p16 in cervical intraepithelial neoplasia (CIN).Methods The expressions of FEZ1 and p16 in 93 cases of CIN and 10 cases of normal cervical specimens were detected by immunohistochemistry.Results The positive expression rates of FEZ 1 were 90.0% (9/10) of normal cervical specimens,67.9% (19/28) of CIN I,36.0% (9/25) of CIN Ⅱ,22.5%(9/40) of CIN Ⅲ.The positive expression rates of p16 were 10.0%(1/10) of normal cervical specimens,32.1%(9/28) of CIN I,76.0%(19/25) of CIN Ⅱ,92.5%(37/40) of CIN Ⅲ.There were significant differences in the positive expression rates of FEZ1 and p16 between CIN Ⅰ and CIN Ⅲ (P 〈 0.01),there was no significant difference in the positive expression rates of FEZ1 and p16 between CIN Ⅱ and CIN Ⅲ.The expression of FEZ1 and p16 was negatively correlation in CIN (r =-0.712,P〈 0.01).Conclusion The abnormal high expression of p16 and abnormal low expression of FEZ1 in CIN may be involved in the occurrence and development of CIN,detecting the expressions of the two indexes may be helpful for clinical diagnosis.
出处 《中国医师进修杂志》 2013年第12期3-6,共4页 Chinese Journal of Postgraduates of Medicine
关键词 宫颈上皮内瘤样病变 免疫组织化学 FEZ1 Cevical intraepithelial neoplasia Immunohistochemistry FEZ1
  • 相关文献

参考文献19

  • 1el Hamidi A, Kocjan G, Du MQ. Clonality analysis of archival cervical smears. Correlation of monoclonality with grade and clinical behavior of cervical intraepithelial neoplasia. Acta Cytol, 2003,47(2) : 117-123.
  • 2Ishii H, Baffa R, Numata SI,et al. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in muhiplehuman tumors. Proc Nail Acad Sci U S A, 1999,96 (7) : 3928-3933.
  • 3Ishii H, Vecchione A, Murakumo Y,et al. FEZ1/I.ZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Nail Acad Sci U S A, 2001,98(18) : 10374-10379.
  • 4Toyooka S, Carbone M, Toyooka KO,et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene, 2002,21 (27) : 4340-4344.
  • 5Veechione A, Ishii H, Baldassarre G, et al. FEZ1/LZTS1 is down- regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol, 2002,160(4) : 1345-1352.
  • 6Toyooka S, Fukuyama Y, Wistuba Ⅱ, et al. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res, 2002,8(7 ) :2292-2297.
  • 7Nonaka D, Fabbfi A, Roz L,et al. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. Cancer Res, 2005,65(4) : 1207-1212.
  • 8Vecchione A, Ishii H, Shiao YH, et al. Fezl/lztsl alterations in gastric carcinoma. Clin Cancer Res, 2001,7(6) : 1546-1552.
  • 9Califano D, Pignata S, Pisano C,et al. FEZ1/LZTS1 protein expression in ovarian cancer. J Cell Physiol, 2010,222 (2):382- 386.
  • 10Chen L, Zhu Z, Sun X,et al. Down-regulation of tumor suppressor gene FEZ1/I.ZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat, 2009,116(3):471-478.

同被引文献21

  • 1Katki H A,Wentzensen N.How might HPV testing be integrated into cervical screening[J].Lancet Oncol,2012,13(1):8-10.
  • 2Clinton L K,Miyazaki K,Ayabe A,et al.The LAST guidelines in clinical practice: implementing recommendations for p16 use[J].Am J Clin Pathol,2015,144(6):844-849.
  • 3Thrall M J.Effect of lower anogenital squamous terminology recommenriations on the use of p!6 immunohistochemistry and the proportion of high-grade diagnoses in cervical biopsy specimens[J].Am J Clin Pathol,2016,145(4):524-530.
  • 4Miyamoto S,Hasegawa J,Morioka M,et al.The association between pl6 and Ki-67 imraunohistostaining and the progression of cervical intraepithelial neoplasia grade 2[J].Int J Gynaecol Obstet,2016,134(1 ):45-48.
  • 5Gan X,Lin X,He R,et al.Prognostic and clinicopathological significance of downregulated pl6 expression in patients with ? bladder gancer: a systematic review and meta-analysis[J].Dis Markers,2016,2016( 1 ):1-13.
  • 6Hiroshima K,Wu D,Hasegawa M,et al.Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with FISH analysis of pl6[J].Diagn Gytopathol,2016,44(7):591-598.
  • 7Mahajan A.Practical issues in the application of pl6 immunohistochemistry in diagnostic pathology[J].Hum Pathol,2016,51:64-74.
  • 8Wentzensen N,Fetterman B,Castle P E,et al.p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women[J]J Natl Cancer Inst,2015,107(12): djv257.
  • 9Possati-Resende J C,Fregnani J H,Kerr L M,et al.The accuracy of p16/Ki-67 and HPV test in the detection of CIN2/3 in women diagnosed with ASC-US or LSIL[J].PLos One,2015,10(7): e0134445.
  • 10Dmitrenko A P.Lateral differences in Ki-67 in breast cancer[J].Mol Clin Oncol,2016,4(6):1041-1044.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部